LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

Kodu・Aktsiate loetelu・Sana Biotechnology Inc

Sana Biotechnology Inc

Suletud

SektorTervishoid

2.68 -3.6

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.66

Max

2.84

Põhinäitajad
By Trading Economics
Sissetulek	-17M -59M
Töötajad	142
EBITDA	-11M -50M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+242.96% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-273M 833M
Eelmine avamishind	6.28
Eelmine sulgemishind	2.68

Uudiste sentiment

By Acuity

50%

169 / 349 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

1.68 / 1.87 Toetus ja vastupanu

Sana Biotechnology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

30. märts 2026, 23:15 UTC

Uudisväärsed sündmused

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

30. märts 2026, 22:36 UTC

Uudisväärsed sündmused

Australian Government Rules Out Boots on the Ground in the Middle East

30. märts 2026, 22:13 UTC

Omandamised, ülevõtmised, äriostud

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

30. märts 2026, 21:00 UTC

Tulu

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

30. märts 2026, 20:15 UTC

Uudisväärsed sündmused

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

30. märts 2026, 23:40 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30. märts 2026, 23:40 UTC

Market Talk

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

30. märts 2026, 23:36 UTC

Market Talk

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

30. märts 2026, 23:12 UTC

Market Talk

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

30. märts 2026, 22:49 UTC

Market Talk

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

30. märts 2026, 22:44 UTC

Market Talk

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

30. märts 2026, 22:43 UTC

Market Talk

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

30. märts 2026, 22:42 UTC

Market Talk

South32 Should Go for Growth, Says New Bull -- Market Talk

30. märts 2026, 22:18 UTC

Market Talk

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

30. märts 2026, 22:05 UTC

Market Talk

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

30. märts 2026, 21:58 UTC

Omandamised, ülevõtmised, äriostud

Sun Life Financial Agrees to Buy Bell Partners for $350M

30. märts 2026, 21:39 UTC

Omandamised, ülevõtmised, äriostud

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

30. märts 2026, 21:38 UTC

Omandamised, ülevõtmised, äriostud

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

30. märts 2026, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

30. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

30. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

30. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

30. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

30. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

30. märts 2026, 21:25 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30. märts 2026, 21:25 UTC

Market Talk

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

30. märts 2026, 21:03 UTC

Omandamised, ülevõtmised, äriostud

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

30. märts 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

30. märts 2026, 20:09 UTC

Tulu

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

30. märts 2026, 20:00 UTC

Uudisväärsed sündmused

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Võrdlus sarnastega

Hinnamuutus

Sana Biotechnology Inc Prognoos

Hinnasiht

By TipRanks

242.96% tõus

12 kuu keskmine prognoos

Keskmine 9.5 USD 242.96%

Kõrge 12 USD

Madal 7 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Sana Biotechnology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Sana Biotechnology Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.68 / 1.87Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There are no events.

Sentiment

By Acuity

169 / 349 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.